J
Julie M. Legler
Researcher at National Institutes of Health
Publications - 22
Citations - 7897
Julie M. Legler is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Prostate cancer & Prostate-specific antigen. The author has an hindex of 19, co-authored 22 publications receiving 7512 citations. Previous affiliations of Julie M. Legler include Harvard University.
Papers
More filters
Journal ArticleDOI
Development of a comorbidity index using physician claims data.
TL;DR: A comorbidity index that incorporates the diagnostic and procedure data contained in Medicare physician (Part B) claims and demonstrates the utility of a disease-specific index using an alternative method of construction employing study-specific weights.
PHARMACOEPIDEMIOLOGY REPORT Development of a comorbidity index using physician claims data
TL;DR: This article developed a comorbidity index that incorporates the diagnostic and procedure data contained in Medicare physician (Part B) claims, which significantly contributes to models of 2-year noncancer mortality and treatment received in both patient cohorts.
Journal ArticleDOI
Overdiagnosis Due to Prostate-Specific Antigen Screening: Lessons From U.S. Prostate Cancer Incidence Trends
Ruth Etzioni,David F. Penson,Julie M. Legler,Dante di Tommaso,Rob J. de Boer,Peter H. Gann,Eric J. Feuer +6 more
TL;DR: The results suggest that the majority of screen-detected cancers diagnosed between 1988 and 1998 would have presented clinically and that only a minority of cases found at autopsy would have been detected by PSA testing.
Journal ArticleDOI
Cancer Surveillance Series: Interpreting Trends in Prostate Cancer—Part I: Evidence of the Effects of Screening in Recent Prostate Cancer Incidence, Mortality, and Survival Rates
Benjamin F. Hankey,Eric J. Feuer,Limin X. Clegg,Richard B. Hayes,Julie M. Legler,Phillip C. Prorok,Lynn A. G. Ries,Ray M. Merrill,Richard Kaplan +8 more
TL;DR: The decline in the incidence of distant stage disease holds the promise that testing for prostate-specific antigen may lead to a sustained decline in prostate cancer mortality, however, population data are complex, and it is difficult to confidently attribute relatively small changes in mortality to any one cause.
Journal ArticleDOI
Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study.
Arnold L. Potosky,Julie M. Legler,Peter C. Albertsen,Janet L. Stanford,Frank D. Gilliland,Ann S. Hamilton,J. William Eley,Robert A. Stephenson,Linda C. Harlan +8 more
TL;DR: There are important differences in urinary, bowel, and sexual functions over 2 years after different treatments for clinically localized prostate cancer and these outcome differences reflect treatment delivered to a heterogeneous group of patients in diverse health care settings.